3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
6
Withdrawn
1
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Plasma cell
1
Myeloid
1
Gynecologic
1
Classical hematology
1
Conditions
Polycythemia Vera
1
Myeloproliferative Disorders
1
Interventions
Specimen Handling
3
Biopsy
3
venetoclax
2
selinexor
2
luspatercept
2
Tacrolimus
2
Lymphatic Irradiation
2
Imatinib Mesylate
2
Busulfan
2
Azacitidine
2
trametinib
1
tagraxofusp
1
peginterferon alfa-2b
1
olutasidenib
1
nilotinib
1
flumatinib
1
fludarabine phosphate
1
fludarabine
1
decitabine and cedazuridine drug combination
1
dabrafenib
1
Tyrosine Kinase Inhibitors
1
Thiotepa
1
Spectroscopy, Near-Infrared
1
Sirolimus
1
Single-Cell Gene Expression Analysis
1
Resistance Training
1
Receptors, Antigen, T-Cell
1
Quality of Life
1
Pleurodesis
1
Phlebotomy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Aspirin
×
Myeloid
×
Clear all
NCT06290765
2025-07-31
PV
PharmaEssentia
Phase 4
Not yet recruiting
70 enrolled